Hybio Pharmaceutical announced that the company's Exenatide Injection has been approved for market by the National Medical Products Administration. The specifications are 5μg and 10μg, with packaging options of 1 vial/box and 3 vials/box. Exenatide is a GLP-1 analogue used to improve blood sugar control in patients with type 2 diabetes.
翰宇药业：艾塞那肽注射液获批上市
Hybio Pharmaceutical: Exenatide Injection approved for market
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated